Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Raymond James Adjusts Mobileye Global Inc. (MBLY) to $16, Cites Earnings Leverage Potential

Raymond James Adjusts Mobileye Global Inc. (MBLY) to $16, Cites Earnings Leverage Potential

FinvizFinviz2026/02/25 02:33
By:Finviz

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now.

On January 24, Raymond James lowered its price target on Mobileye Global Inc. (NASDAQ:MBLY) to $16 from $19 while maintaining an Outperform rating following fourth-quarter results. The firm reiterated that fiscal 2026 is expected to represent a transitional year but sees potential upside emerging in late 2026. Raymond James highlighted favorable risk-reward dynamics, citing meaningful earnings leverage as incremental revenue scales.

Raymond James Adjusts Mobileye Global Inc. (MBLY) to $16, Cites Earnings Leverage Potential image 0

The prior day, RBC Capital reduced its price target on Mobileye Global Inc. (NASDAQ:MBLY) to $13 from $14 and maintained a Sector Perform rating after reviewing fourth-quarter results. Fiscal 2026 EBIT guidance came in below consensus, reflecting increased research and development expenses associated with the Mentee Robotics acquisition. While RBC remains constructive on the company’s robotaxi and humanoid robotics initiatives, it noted near-term headwinds from OEM insourcing of advanced autonomy capabilities.

On January 22, Mobileye Global Inc. (NASDAQ:MBLY) reported full-year 2025 revenue of $1.9 billion, representing 15% year-over-year growth and modestly exceeding prior guidance. The company introduced artificial community intelligence (ACI) for planning, advanced sim-to-wheel transfer methodologies, and a fast-think/slow-think vision-language model architecture aimed at enhancing precision, scalability, and reducing teleoperator dependency. The robotics acquisition expands the platform into vertically integrated humanoid systems featuring continuous passive learning, with customer proof-of-concept engagements expected in high double digits during 2026 and commercialization targeted for 2028, generating synergies with Mobileye’s simulation and AI stack. Although fiscal 2026 may reflect elevated investment, the expansion into robotics and advanced autonomy broadens Mobileye’s total addressable market and enhances long-term optionality, reinforcing the case for patient capital deployment.

Mobileye Global Inc. (NASDAQ:MBLY), headquartered in Israel, develops advanced driver-assistance systems and autonomous driving technologies. The company’s portfolio spans computer vision, mapping, and AI-based decision-making platforms designed for both consumer vehicles and future mobility solutions.

While we acknowledge the potential of MBLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Bojia Investment's Long-term Value Assessment of SpaceX

他山之石观投资2026/08/20 01:11
Bojia Investment's Long-term Value Assessment of SpaceX

mRNA personalized cancer vaccine! What does Moderna’s breakthrough mean?

Goldman Sachs, Citibank, and JPMorgan Chase all believe that Moderna's breakthrough means that mRNA technology has successfully unlocked the oncology pipeline, significantly reducing the risk of melanoma recurrence and metastasis, and demonstrating the enormous potential of mRNA in non-respiratory diseases, setting a milestone in tumor immunotherapy. Goldman Sachs is optimistic about its potential across multiple cancer types; JPMorgan Chase and Citibank are more cautious, pointing out that the commercialization threshold for personalized customization is high, and the efficacy for other cancer types still needs to be verified.

华尔街见闻2026/08/20 00:56

Is the familiar gold bull market back? The U.S. Treasury to repurchase long-term bonds, $4,500 may become the starting point for a new surge

After the U.S. Treasury unexpectedly took steps to control long-term borrowing costs, gold prices recorded their largest increase in six months. The U.S. Treasury announced that it will expand the scale of liquidity support repo operations for 10-year to 30-year securities.

智通财经2026/08/20 00:56
Is the familiar gold bull market back? The U.S. Treasury to repurchase long-term bonds, $4,500 may become the starting point for a new surge